Willow Biosciences Inc. announced that the Board of Directors has appointed Dr. Chris Savile, Willow's Chief Operations Officer, as Chief Executive Officer, effective March 28, 2023, in connection with Dr. Peter Seufer-Wasserthal's retirement as CEO. Dr. Seufer-Wasserthal will continue to be a Director of the Company. Dr. Savile, a leader at Willow since the Company's inception in early 2019.

Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships. Prior to joining Willow, Dr. Savile worked in senior leadership roles at Intrexon Corporation, and Codexis Inc. Chris is an experienced business professional and an accomplished chemist, high-throughput assay scientist, and protein engineer with a strong technical background.